Galunisertib
- Generic Name
- Galunisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N5O
- CAS Number
- 700874-72-2
- Unique Ingredient Identifier
- 3OKH1W5LZE
- Background
Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
- Conditions
- NeoplasmsNeoplasm MetastasisPancreatic Cancer
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 170
- Registration Number
- NCT01373164
- Locations
- 🇺🇸
Florida Hospital Tampa HPG and Foregut Surgery, Tampa, Florida, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT01246986
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT01220271
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.